Javier de la Rubia.

Efficacy October 15 The cutoff date for the ultimate analysis was, 2012. The median follow-up was 40 a few months . The median period to progression to symptomatic disease had not been reached in the treatment group and was 21 a few months in the observation group . The hazard ratio for progression to symptomatic myeloma with treatment was 0.18 . Symptomatic disease developed in 47 patients in the observation group , as compared with 13 sufferers in the treatment group . During maintenance therapy, 24 sufferers experienced biologic progression, and low-dosage dexamethasone was added to the therapy in 18 individuals. With a median follow-up of 26 months , 3 patients acquired a partial response, 11 had steady disease without symptoms, and symptomatic myeloma created in 4.ASH wins six Aster Awards for excellence in healthcare marketing and advertising American Specialty Health Incorporated , a national wellness and health organization, recently announced that it had earned four Gold and two Silver Aster awards for excellence in healthcare advertising. It had been an honor to have American Specialty Health take part in the 2010 Aster Awards Competition. Lucas, Aster Awards System Coordinator. All winners are posted on the Aster Awards site, ( as well as published in Marketing Healthcare Today, a national healthcare marketing magazine.

A.P. Pharma’s third quarter net loss raises to $4.2 million A.P. Pharma, Inc. , a specialty pharmaceutical company, reported financial results for its third one fourth ended September 30 today, 2011 and highlighted its recent corporate progress.0 million private positioning of common warrants and stock.